On Monday, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) opened higher 15.71% from the last session, before settling in for the closing price of $0.71. Price fluctuations for LXRX have ranged from $0.62 to $3.73 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 186.21%. Company’s average yearly earnings per share was noted 14.05% at the time writing. With a float of $168.72 million, this company’s outstanding shares have now reached $361.49 million.
Let’s determine the extent of company efficiency that accounts for 285 employees. In terms of profitability, gross margin is 87.97%, operating margin of -4037.43%, and the pretax margin is -4109.41%.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lexicon Pharmaceuticals Inc is 53.33%, while institutional ownership is 29.64%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.05% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Check out the current performance indicators for Lexicon Pharmaceuticals Inc (LXRX). In the past quarter, the stock posted a quick ratio of 7.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Looking closely at Lexicon Pharmaceuticals Inc (NASDAQ: LXRX), its last 5-days average volume was 6.76 million, which is a jump from its year-to-date volume of 3.66 million. As of the previous 9 days, the stock’s Stochastic %D was 26.99%. Additionally, its Average True Range was 0.11.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 12.68%, which indicates a significant decrease from 51.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 129.35% in the past 14 days, which was higher than the 115.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1798, while its 200-day Moving Average is $1.6748. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $0.8999. Second resistance stands at $0.9728. The third major resistance level sits at $1.1027. If the price goes on to break the first support level at $0.6971, it is likely to go to the next support level at $0.5672. Should the price break the second support level, the third support level stands at $0.4943.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
There are currently 246,237K shares outstanding in the company with a market cap of 298.95 million. Presently, the company’s annual sales total 1,200 K according to its annual income of -177,120 K. Last quarter, the company’s sales amounted to 1,750 K and its income totaled -64,810 K.
